Share

May 2018; 5 (3) ArticleOpen Access

Treatment choices and neuropsychological symptoms of a large cohort of early MS

Olga von Bismarck, Theresa Dankowski, Björn Ambrosius, Nicole Hessler, Gisela Antony, Andreas Ziegler, Muna-Miriam Hoshi, Lilian Aly, Felix Luessi, Sergiu Groppa, Luisa Klotz, Sven G. Meuth, Björn Tackenberg, Muriel Stoppe, Florian Then Bergh, Hayrettin Tumani, Tania Kümpfel, Martin Stangel, Christoph Heesen, Brigitte Wildemann, Friedemann Paul, Antonios Bayas, Clemens Warnke, Frank Weber, Ralf A. Linker, Ulf Ziemann, Uwe K. Zettl, Frauke Zipp, Heinz Wiendl, Bernhard Hemmer, Ralf Gold, Anke Salmen
First published March 1, 2018, DOI: https://doi.org/10.1212/NXI.0000000000000446
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
358

Share

Article Information

vol. 5 no. 3 e446
DOI: 
https://doi.org/10.1212/NXI.0000000000000446
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received November 5, 2017
  • Accepted in final form January 12, 2018
  • First Published March 1, 2018.
Copyright & Usage: 
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Olga von Bismarck, medstudent*,
    2. Theresa Dankowski, PhD*,
    3. Björn Ambrosius, PhD,
    4. Nicole Hessler, Msc,
    5. Gisela Antony, Dipl-Psych,
    6. Andreas Ziegler, PhD,
    7. Muna-Miriam Hoshi, MD,
    8. Lilian Aly, MD,
    9. Felix Luessi, MD,
    10. Sergiu Groppa, MD,
    11. Luisa Klotz, MD,
    12. Sven G. Meuth, MD,
    13. Björn Tackenberg, MD,
    14. Muriel Stoppe, MD,
    15. Florian Then Bergh, MD,
    16. Hayrettin Tumani, MD,
    17. Tania Kümpfel, MD,
    18. Martin Stangel, MD,
    19. Christoph Heesen, MD,
    20. Brigitte Wildemann, MD,
    21. Friedemann Paul, MD,
    22. Antonios Bayas, MD,
    23. Clemens Warnke, MD,
    24. Frank Weber, MD,
    25. Ralf A. Linker, MD,
    26. Ulf Ziemann, MD,
    27. Uwe K. Zettl, MD,
    28. Frauke Zipp, MD,
    29. Heinz Wiendl, MD,
    30. Bernhard Hemmer, MD,
    31. Ralf Gold, MD and
    32. Anke Salmen, MD
    33. On behalf of the German Competence Network Multiple Sclerosis (KKNMS)
  1. Olga von Bismarck, medstudent*,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Theresa Dankowski, PhD*,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Björn Ambrosius, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Commercial, travel grant, 5000? Novartis for AAN 2016

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. FORUM Anschubfinanzierung, Medizinische Faktult?t Ruhr Universit?t Bochum, F?rderkennzeichen: F859-15

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Nicole Hessler, Msc,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Gisela Antony, Dipl-Psych,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) German Ministry of Education and Research, BMBF 01GI1304A, PI "Core Unit IT KKNMS", 2013-2016 (2) German Ministry of Education and Research, BMBF 01GI1601B, PI "Core Unit IT KKNMS", 2016-2019 (3) German Ministry of Education and Research, BMBF 01GM1514C, PI "Core Unit IT Dystonia Network", 2016-2019 (4) EU, EU-FP7-305653, PI "Core Unit IT chILD-EU (European Management Platform for Childhood Interstitial Lung Diseases)", 2016

    Research Support, Academic Entities:

    1. University Marburg, Leader Central Information Office Competence Network Parkinson, 2016

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Andreas Ziegler, PhD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. German Ministry of Education and Research, 01GI1601G, PI, 2015-2018

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Muna-Miriam Hoshi, MD,
    8. Scientific Advisory Boards:

    1. scientific advisory board for Merck Serono

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. travel grant from Bayer Health Care

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Lilian Aly, MD,
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Felix Luessi, MD,
    10. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. Travel grants from Teva Pharma

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Sergiu Groppa, MD,
    11. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. Luisa Klotz, MD,
    12. Scientific Advisory Boards:

    1. (1) Genzyme (2) Novartis (3) Biogen

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Novartis, speaker honoraria and travel support (2) Merck Serono, speaker honoraria and travel support (3) CSL Behring, speaker honoraria and travel support

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Novartis (2) Biogen

    Research Support, Government Entities:

    1. (1) (CRC) SFB TR-128 Impact of dietary factors on the gut-CNS-axis ? implications for CNS autoimmunity A08, Project leader, 2016-2020 (2) (CRC) SFB 1009 ?Immune-cell interactions with endothelial cells and pericytes at the blood-brain- barrier: mechanisms and consequences? A03, Sub-project Leader, 2012-2020 (3) Federal Ministry of Education and Research (BMBF) Competence Network Multiple Sklerose: ?Multi-parameter immune cell-profiling: identification of biosignatures to understand heterogeneity, prognosis and treatment response factors in MS?, 3.1 Sub-project Leader, 2016-2020

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  12. Sven G. Meuth, MD,
    13. Scientific Advisory Boards:

    1. (1) Almirall (2) Bayer Health Care (3) Biogen (4) Genzyme (5) Merck Serono (6) Novartis (7) Novo Nordisk (8) Roche (9) Sanofi-Aventis (10) Teva (11) Diamed (12) MedDay Pharmaceuticals (13) ONO Pharma

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Almirall, travel or speaker honoraria (2) Bayer Health Care, travel or speaker honoraria (3) Biogen, travel or speaker honoraria (4) Genzyme, travel or speaker honoraria (5) Merck Serono, travel or speaker honoraria (6) Novartis, travel or speaker honoraria (7) Novo Nordisk, travel or speaker honoraria (8) Roche, travel or speaker honoraria (9) Sanofi-Aventis, travel or speaker honoraria (10) Teva, travel or speaker honoraria (11) Diamed, travel or speaker honoraria (12) MedDay Pharmaceuticals, travel or speaker honoraria (13) ONO Pharma

    Editorial Boards:

    1. PLoS One

    Patents:

    1. (1)Effectivity of specific FXII/FXIIa inhibitors, particularly rHA-Infestin 4 used to treat neuro- inflammatoral diseases (WO 2013/113774 A1 and EP 2 263 110 A1) (2) Diagnosis of a novel autoimmune disease (European patent; 15001186.4 ? 1402) (3)

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Almirall (2) Bayer Health Care (3) Biogen (4) Genzyme (5) Merck Serono (6) Novartis (7) Novo Nordisk (8) Roche (9) Sanofi-Aventis (10) Teva (11) Diamed (12) MedDay Pharmaceuticals (13) ONO Pharma

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Almirall (2) Bayer Health Care (3) Biogen (4) Genzyme (5) Merck Serono (6) Novartis (7) Novo Nordisk (8) Roche (9) Sanofi-Aventis (10) Teva (11) Diamed (12) MedDay Pharmaceuticals (13) ONO Pharma

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  13. Björn Tackenberg, MD,
    14. Scientific Advisory Boards:

    1. Served on scientific advisory boards for (1) Biogen-idec Germany and USA, (2) Bayer Healthcare Germany and USA, (3) Novartis Germany, (4) Merck-Serono Germany, (5) Octapharma Germany, (6) CSL Behring Germany, (7) GRIFOLS Germany

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. received speaker honoraria from (1) Biogen-idec Germany and USA, (2) Bayer Healthcare Germany and USA, (3) Novartis Germany, (4) Merck-Serono Germany, (5) TEVA Germany, (6) Sanofi-Aventis Germany, (7) Octapharma Germany, (8) CSL Behring Germany, (9) GRIFOLS Germany, (10) GSK Germany

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. received Consultancy fees from (1) Biogen-idec Germany and USA, (2) Bayer Healthcare Germany and USA, (3) Novartis Germany, (4) Merck-Serono Germany, (5) Octapharma Germany, (6) CSL Behring Germany, (7) GRIFOLS Germany

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Bayer Healthcare Germany, (2) Biogen-idec Germany, (3) Novartis Germany, (4) Sanofi-Aventis Germany

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. (1) Marburg University Trust

    Research Support, Foundations and Societies:

    1. F?rderverein Neurologie e. V. (FN). German Myasthenia gravis Society (DMG). German Society of Neurology (DGN)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  14. Muriel Stoppe, MD,
    15. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  15. Florian Then Bergh, MD,
    16. Scientific Advisory Boards:

    1. Speaker honoraria and consultancy fees as a speaker and advisor from Bayer Healthcare, Biogen, Merck Serono, Novartis, Roche, Sanofi Genzyme, and TEVA.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Actelion, Novartis, TEVA

    Research Support, Government Entities:

    1. German Federal Ministry of Research; Deutsche Forschungsgemeinschaft (DFG, federal research funding agency)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  16. Hayrettin Tumani, MD,
    17. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  17. Tania Kümpfel, MD,
    18. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. I have received travel expenses and personal compensations for lectures from Bayer Healthcare, Teva Pharma, Merck, Novartis Pharma, Sanofi-Aventis/Genzyme, CLB Behring, Roche Pharma and Biogen as well as grant support from Bayer-Schering AG, Novartis and Chugai Pharma

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  18. Martin Stangel, MD,
    19. Scientific Advisory Boards:

    1. Biogen, Baxalta/Shire, CSL Behring, Grifols, MedDay, Merck-Serono, Novartis, Roche, Sanofi-Genzyme, Teva

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Travel and speaker honoraria from Bayer Healthcare, Biogen, CSL Behring, Merck-Serono, Novartis, Roche, Sanofi-Genzyme, and Teva

    Editorial Boards:

    1. PLoS ONE, Academic Editor; Multiple Sclerosis International, Editorial Board Member

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen, Merck-Serono, Novartis, Sanofi-Genzyme, Teva

    Research Support, Government Entities:

    1. Deutsche Forschungsgemeinschaft (DFG), Bundesministerium f?r Bildung und Forschung (BMBF), EU FP7

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Volkswagenstiftung

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  19. Christoph Heesen, MD,
    20. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Received speaker honoraries from Biogen, Merck, Genyzme, Novartis

    Editorial Boards:

    1. International Journal of MS Care, 2014 until now

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. Received Research grants from Genzyme, Biogen, Roche, Novartis, Merck, Roche.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Genzyme Sanofi Aventis Biogen Novartis Roche

    Research Support, Government Entities:

    1. German Minstery of Research, PI 2012-2016 Hertie Foundation, PI 2014-2016

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NMSS

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  20. Brigitte Wildemann, MD,
    21. Scientific Advisory Boards:

    1. Brigitte Wildemann served on scientific advisory boards for Novartis, Sanofi Genzyme, Roche

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Brigitte Wildemann has received personal fees from Biogen, Merck Serono, Novartis Pharmaceuticals, TEVA Pharma, and from Sanofi Genzyme

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Brigitte Wildemann reports grants from Bundesministerium f?r Forschung und Technologie, grants from Dietmar Hopp Stiftung, grants from Klaus Tschira Stiftung, grants from Merck Serono, Novartis Pharmaceuticals, and from Sanofi Genzyme

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  21. Friedemann Paul, MD,
    22. Scientific Advisory Boards:

    1. Novartis OCTIMS study steering committee MedImmune steering committee

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. speaker honoraria and travel grants from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono, Alexion, Chugai, MedImmune, Shire

    Editorial Boards:

    1. Academic Editor, PLoS ONE Associate Editor, Neurology Neuroimmunology and Neuroinflammation

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. consultancies for SanofiGenzyme, BiogenIdec, MedImmune, Shire, Alexion

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research support from from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, Alexion and Merck Serono

    Research Support, Government Entities:

    1. German Research Council (DFG Exc 257), Werth Stiftung of the City of Cologne, German Ministry of Education and Research (BMBF Competence Network Multiple Sclerosis), Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program (combims.eu)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, National Multiple Sclerosis Society of the USA

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  22. Antonios Bayas, MD,
    23. Scientific Advisory Boards:

    1. (1) Merck Serono (2) Biogen (3) Novartis (4) TEVA (6) Sanofi/Genzyme (7) Roche

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Merck Serono: travel, speaker honoraria (2) Biogen: travel, speaker honoraria (3) Novartis: travel, speaker honoraria (4) TEVA: travel, speaker honoraria (6) Sanofi/Genzyme: travel, speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Merck Serono (2) Biogen (3) Novartis

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  23. Clemens Warnke, MD,
    24. Scientific Advisory Boards:

    1. Biogen, Novartis

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Speakers honoraria Novartis, Biogen, Bayer, Teva.

    Editorial Boards:

    1. Frontiers in Neurology, associate editor, 2016-2018

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Hertie foundation, Charcot foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  24. Frank Weber, MD,
    25. Scientific Advisory Boards:

    1. Genzyme Novartis

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Biogen Speaker honoraria TEVA Speaker honoraria Merck-Serono travel grant Novartis travel grant Pfizer Speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Sana, head of neurological clinic, since 01.01.2018

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Merck-Serono Novartis

    Research Support, Government Entities:

    1. BMBF

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  25. Ralf A. Linker, MD,
    26. Scientific Advisory Boards:

    1. Biogen, Genzyme, Merck,Novartis, Roche, TEVA.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Biogen, Genzyme, Merck, Novartis, Roche, TEVA.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Biogen, Novartis, Roche.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen, Novartis.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  26. Ulf Ziemann, MD,
    27. Scientific Advisory Boards:

    1. (1) CorTec GmbH

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Bayer Vital GmbH, speaker honorarium (2) Biogen Idec GmbH, speaker honorarium (3) Bristol Myers Squibb GmbH, speaker honorarium (4) Medtronic GmbH, speaker honorarium (5) Pfizer Pharma GmbH, speaker honorarium

    Editorial Boards:

    1. (1) Clinical Neurophysiology, Editor-in-Chief, 2 years (2) Journal of Neuroscience, Associate Editor, 3 years (3) Brain Stimulation, Deputy Editor, 10 years (4) Experimental Brain Research, Editorial advisory board member, 13 years

    Patents:

    1. NONE

    Publishing Royalties:

    1. (1) Lehrbuch Neurologie, Elsevier, 2011 (2) Das TMS Buch, Springer, 2007 (3) The Oxford Handbook of Trancranial Stimulation, Oxford University Press, 2007

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. (1) Biogen Idec GmbH, Investigator initiated trial (2) Janssen Pharmaceuticals NV, Investigator initiated trial (3) Servier, Investigator initiated trial

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  27. Uwe K. Zettl, MD,
    28. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. Speakers honoraria and travel grants from Bayer Pharma, Aventis Pharma, TEVA Pharma, Merck-Serono Pharma, Biogen-Idec Pharma.

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  28. Frauke Zipp, MD,
    29. Scientific Advisory Boards:

    1. (1)Teva (2) Merck Serono (3) Novartis (4) Bayer Healthcare (5) Biogen Idec Germany (6) ONO (7) Genzyme (8) Sanofi-Aventis (9) Octapharma

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1)Teva (2) Merck Serono (3) Novartis (4) Bayer Healthcare (5) Biogen Idec Germany (6) ONO (7) Genzyme (8) Sanofi-Aventis (9) Octapharma

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Teva (2) Merck Serono (3) Novartis (4) Bayer

    Research Support, Government Entities:

    1. (1) DFG CRC-TRR 128, Co-Spokesperson/Spokesperson, 2012-2020 (2) DFG CRC1080, PI, 2013-2020 (3) BMBF KKNMS, PI, 2013-2019

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Progressive MS Alliance, BRAVEinMS (2) Patient-Centered Outcomes Research Institute (PCORI), PRAG-MS

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  29. Heinz Wiendl, MD,
    30. Scientific Advisory Boards:

    1. (1) Bayer Healthcare (2) Biogen Idec (3) Sanofi- Genzyme (4) Merck Serono (5) Novartis (6) Roche (7) Teva

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Bayer Vital GmbH (2) Bayer Schering AG (3) Biogen (4) CSL Behring (5) EMD Serono (6) Fresenius Medical Care (7) Sanofi - Genzyme (8) Merck Serono (9) Omniamed (10) Novartis (11) Teva (12) GlaxoSmithKline (13) GW Pharmaceuticals

    Editorial Boards:

    1. (1) PLOS ONE, Editorial board member, since 2013 (2) Neurotherapeutics, since 2013 (3) Recent Patents on Inflammation & Allergy Drug Discovery

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Biogen (2) Merck Serono (3) Novartis (4) Omniamed (5) Roche (6) Sanofi-Genzyme

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Bayer Healthcare (2) Bayer Vital (3) Biogen (4) Merck Serono (5) Novartis (6) Sanofi ? Genzyme (7) Sanofi US (8) TEVA Pharma

    Research Support, Government Entities:

    1. (1) German Ministry for Education and Research (BMBF), 01GI1601E, principal investigator, 2016-2019 (2)Interdisciplinary Centre of Clinical Research (IZKF) Muenster, principal investigator, 2015-2018 (4)PML Consortium, principal investigator, 2016-2018 (5) German Research Foundation, principal investigator,SFB 1009 TP A3 + SFB-TR CRC128 TP A09 + SFB TR CRC128 TP A10, TR CRC128 TP V, TR CRC128 TP Z02 2016- 2020

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Else Kr?ner Fresenius Foundation (2) Fresenius Foundation (3) Hertie Foundation (4) RE Children?s Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  30. Bernhard Hemmer, MD,
    31. Scientific Advisory Boards:

    1. Advisory Boards for F. Hoffmann-La Roche Ltd, Novartis, Bayer AG, and Genentech; he has served as DMSC member for AllergyCare

    Gifts:

    1. Me or my institution have received speaker honoraria from Biogen Idec, Teva Neuroscience, Merck Serono, Medimmune, Novartis, Desitin, Hoffman-LaRoche

    Funding for travel or speaker honoraria:

    1. Excemed

    Editorial Boards:

    1. Editorial board member of Jama Neurology and MS Journal

    Patents:

    1. I hold part of two patents; one for the detection of antibodies a n d T c e l l s a g a i n s t K I R 4 . 1 i n a s u b p o p u l a t i o n o f M S p a t i e n t s a n d o n e f o r g e n e t i c d e t e r m i n a n t s o f neutralizing antibodies to interferon β

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Chugai Pharmaceuticals

    Research Support, Government Entities:

    1. German Research foundation, German Ministry of Education and Research, EU Horizon 2020, EU IMI

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  31. Ralf Gold, MD and
    32. Scientific Advisory Boards:

    1. (1) TEVA Laquinimod DSMB

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Speaker honoraria from Biogen, Genzyme, TEVA, Merckserono, BayerSchering,Ozgene, Novartis

    Editorial Boards:

    1. SAGE Journal, Aktuelle Neurologie, Experimental Neurology

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  32. Anke Salmen, MD
    33. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. speaker honoraria and/or travel compensation for activities with Almirall Hermal GmbH, Biogen, Merck, Novartis, Roche, and Sanofi Genzyme; none related to this work.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (O.v.B., B.A., R.G., A.S.), St. Josef-Hospital, Ruhr-University Bochum; Institute of Medical Biometry and Statistics (T.D., N.H., A.Z.), University of Lübeck, University Hospital Schleswig-Holstein, Campus Lübeck; Central Information Office (CIO) (G.A.), Philipps-University Marburg, Germany; School of Mathematics (A.Z.), Statistics and Computer Science, University of KwaZulu-Natal, Pietermaritzburg, South Africa; Department of Neurology (M.-M.H., L.A., B.H.), Klinikum rechts der Isar, Technical University of Munich; Munich Cluster for Systems Neurology (SyNergy) (L.A., B.H.); Department of Neurology (F.L., S.G., F.Z.), University Medicine Mainz, Johannes Gutenberg University Mainz; Department of Neurology (L.K., S.G.M., H.W.), University Hospital Münster; Department of Neurology (B.T.), Philipps-University Marburg; Department of Neurology (M.Stoppe, F.T.B.), University of Leipzig; Department of Neurology (H.T.), University of Ulm; Clinic of Neurology Dietenbronn (H.T.), Schwendi; Institute of Clinical Neuroimmunology (T.K.), Ludwig Maximilian University of Munich; Department of Neurology (M.Stangel), Hannover Medical School; Institut für Neuroimmunologie und Multiple Sklerose (C.H.), Universitätsklinikum Hamburg-Eppendorf; Department of Neurology (B.W.), University of Heidelberg; NeuroCure Clinical Research Center and Experimental and Clinical Research Center (F.P.), Charité—University Medicine Berlin and Max Delbrueck Center for Molecular Medicine; Department of Neurology (A.B.), Klinikum Augsburg; Department of Neurology (C.W.), Heinrich-Heine-University, Düsseldorf; Department of Neurology (C.W.), University Hospital Köln; Neurology (F.W.), Max-Planck-Institute of Psychiatry, Munich; Neurological Clinic (F.W.), MATERNUS Kliniken AG, Bad Oeynhausen; Department of Neurology (R.A.L.), University Hospital Erlangen; Department of Neurology & Stroke (U.Z.), Hertie Institute for Clinical Brain Research, Eberhard-Karls-University Tübingen; Department of Neurology (U.K.Z.), University of Rostock, Germany; and Department of Neurology (A.S.), Inselspital Bern, University Hospital and University of Bern, Switzerland.
  1. Correspondence
    Dr. Salmen anke.salmen{at}insel.ch
View Full Text

Article usage

Article usage: March 2018 to March 2019

AbstractFullPdfSource
Mar 2018028371Highwire
Apr 2018012323Highwire
Apr 2018213438pmc
May 20180101965Highwire
Jun 2018016728Highwire
Jun 201882028pmc
Jul 2018012316Highwire
Aug 201817212Highwire
Aug 201831314pmc
Sep 201807018Highwire
Oct 2018135411Highwire
Nov 20183849Highwire
Dec 20180655Highwire
Jan 20192764Highwire
Feb 20196816Highwire
Mar 2019520710Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.nn.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Letters

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Letters Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Advertisement